ç±³CDCè«æðµã³ããã¯ãµã«ããããããªã 远èšãã
â»è¿œèšã¯äžçªäžã«
ã³ããã®çå®ã远æ±ããããªãã¿ãã ã»ã³ãŒã¯ã³å士ð
圌ã®åè«è©ããµã«ã®è
è现èã ããã³ãããè²ãŠããïŒ2020幎10æïŒ
é¢çœããŠçºèŠãå€ãæãªã®ã§ããã®ããã°ãªãã«ãŸãã£ãšãŸãšããŠã¿ãŸããã
ããã¯2020幎1æã®ç±³CDCã³ããåé¢è«æïŒçºè¡šå幎6æïŒã解説ãããã®ã§ãã
ã¢ã¡ãªã«ã§ãååšèšŒæããåºãããå Žåã¯ãããŠãããã§ã
ãã®è«æã«ã€ããŠã®å士ã®è§£èª¬ãåŒçšããŸãð
ã»éºäŒåè§£æã«ã€ããŠ
ãŸãããå
šã²ãã é
åãã®é
ã§ã¯ããŠã€ã«ã¹ãåé¢ããŠã²ãã ã®ç«¯ãã端ãŸã§é
åãæ±ºå®ããã®ã§ã¯ãªããPCRãããŒãã䜿ã£ãŠçŽç²åããŠããªããµã³ãã«ãã37åã®å¡©åºå¯ŸãèŠã€ããããšãæžãããŠããã
ã€ãŸããç¡å·ã®ãŠã€ã«ã¹ã®ã²ãã ãšãããçŽ3äžåã®å¡©åºå¯Ÿã®ãã¡ãå®éã«ã¯37åã調ã¹ããšããããšã ã
ãããŠããã®37åã®ã»ã°ã¡ã³ããã³ã³ãã¥ãŒã¿ããã°ã©ã ã«å
¥åããæ®ãã®å¡©åºå¯ŸãåããŠãã£ãã®ã§ããã
å³äžæ®µã®37å¡©åºã3äžå¡©åºãšã¯ããããããšã§ãã
ç§ã«ãšã£ãŠããã®ã³ã³ãã¥ãŒã¿çæã®ã¹ãããã¯ç§åŠçãªäžæ£è¡çºã ããããšåããããªããšãèšããã
ããç ç©¶è
ã°ã«ãŒãããè¹ã®äžéšãå°»å°Ÿã®æ¯ãè§ã®æçãçºèŠããããšã§ããŠãã³ãŒã³ãçºèŠãããšäž»åŒµããã
ãããŠããããã®æ
å ±ãã³ã³ãã¥ãŒã¿ã«å
¥åãããŠãã³ãŒã³ãåçŸããããã«ããã°ã©ã ãããã®ã³ã³ãã¥ãŒã¿ã«ããåçŸãæ¬ç©ã®ãŠãã³ãŒã³ã ãšäž»åŒµããã
ãã¡ããã圌ãã¯å®éã«ãŠãã³ãŒã³ãèŠãããšããªãã®ã§ãå®éã®ãŠãã³ãŒã³ã®æ¯ãè¹ãè§ãšæ¯èŒããããã«ããã®éºäŒåæ§é ã調ã¹ãããšã¯ã§ããªãã£ãã ããã
ãŠãã³ãŒã³ïŒã€ã¡ãŒãžã§ããååšèšŒæã¯ãããŸããïŒ
ãã®è©±ãå¥ã®äŸã§ãããšãäŸãã°ãžã°ãœãŒããºã«ããã£ãšããéã«çµã¿ç«ãŠãã³ã³ãã¥ãŒã¿ãœããããã£ããšããŸããå°ããããæ¬ ããããŒã¹ããã£ãŠãããŸãæ³åã§äœã£ãŠããŸããããªã
ããã«37ããŒã¹ã ãå
¥ããŠå
š3äžããŒã¹ã®ããºã«ãæšæž¬ã§æ§ç¯ãããã®ã§ãã
ã²ãã æ§ç¯ã³ã³ãã¥ãŒã¿ã¯äžéšã®äººãïŸç³ã®ããã«åŽãããæ¬¡äžä»£ã·ãŒã±ã³ãµãŒããšãããã®ã§ãããããã§ã37ããŒã¹ã3äžã«åºããã®ã¯ãããã«ç¡çããããšããããšã¯èª°ã§ãããããŸãã
ããããã®37ããŒã¹ã¯1æã®çµµã§ã¯ãªãæ§ã
ãªçµµããæã¡å¯ã£ããã©ãã©ã®ãã®ãªã®ã§ãã
37ããŒã¹ã3äžããŒã¹ã«èšããŸããã®ã¯ãã¯ãäžå¯èœãªã®ã§ããåºã«é£Ÿã£ãŠããããã¶ããããšäŒŒãŠãã ããããšæã宿æžã¿ã®ããºã«ãåèã«ããŸãã
ãã®å Žåãäžåœãæåã«çºè¡šããã³ããéºäŒåããŒã¿ã»NC045512ãåºã«37ã²ãã ãäœã£ãŠããŸãããã®äžåœããŒã¿èªäœãã¿ã©ã¡ãªãã®ãªã®ã«ã§ãã
CDCè«æããð
ïŒæã ã¯ãã³ãããŠã€ã«ã¹åç §é å (GenBank ã¢ã¯ã»ãã·ã§ã³çªå· NC045512) ã«åºã¥ããŠãã²ãã ã«ããã37察ã®ãã¹ãããPCR ãèšèšããã
ãããã£ãŠäœãã²ãã ãããã°ã©ã ã«ããäœéããã®ããŒãžã§ã³ãã§ããŸãð
ç ç©¶è
ãã¡ã¯ãSARS-CoV-2ã®æ¬åœã®ã²ãã ãã©ããªã®ãããã³ã³ã»ã³ãµã¹ãïŒæç¥šã®ãããªãã®ïŒã«ãã£ãŠæ±ºãããšäž»åŒµããŠããã
ãã®å Žåããã³ã³ãã¥ãŒã¿ãŒããã°ã©ã ã«ãã£ãŠãæ¶ç©ºã®ããŠãã³ãŒã³ãã®ããŒãžã§ã³ãç°ãªããããã°ã«ãŒãã§éãŸã£ãŠãã©ããæ¬ç©ã®æ¶ç©ºã®ãŠãã³ãŒã³ããæ±ºããã®ã ãšããã
人éãšã³ã³ãã¥ãŒã¿åæ¹ã®æšæž¬ãšä»®å®ïŒãšéœåïŒããµãã ãã«å
¥ã£ãŠå®æããã²ãã ã
ããããŠèŠããšãã²ãã ãšå®éã®ãŠã€ã«ã¹ïŒãããšããŠïŒã¯ãŸãäžèŽããªããããã²ãã ããããããŠã€ã«ã¹ã¯ååšããããªã©ãšã¯å°åºèšããªãããšãããããŸãã
ãããŸã§ã®è©±ãåç»ã§30ç§ã§ð
ïŒ7:40ããïŒ
ããŠããµã«ã®è©±ã¯ããããã§ãã
ïŒã¢ããªã«ãããªã¶ã«ïŒçããè èãåãåºããŠäœã£ãã®ãVero现èã§ã
ãã®ç ç©¶ã®æ¬åœã®æå³ã§ã®å€§çºèŠã¯ããã®åŸã«åºãŠãããããŸãã«ãè¡æçãªçºèŠã ã£ãã®ã§ãç§ã¯èªåãèªãã§ããããšãä¿¡ãããŸã§äœåºŠãèªã¿è¿ããããã®ç®æããã®ãŸãŸåŒçšãããã
ã»CDCè«æããð
ãããã§ãããè
ºãã现èïŒA549ïŒãããèèãã现èïŒHUH 7.0ïŒãããèå
è
现èïŒHEK-293TïŒãããã«Vero E6现èãVero CCL81现èãªã©ãéé·é¡ãããã®äžè¬çãªçŽ°èæ ªãçšããŠãSARS-CoV-2ã®ææã»è€è£œèœåã調ã¹ãã
... åçŽ°èæ ªã«é«åæ°ã§æ¥çš®ããææåŸ24æéåŸã«æ€æ»ãããã
äŸã®çްèå¹é€å®éšã§ããã
ããç±æ¥ã®çްè3çš®ïŒããèå
è
现èãå«ã¿ãŸãïŒã©ããã調éããâŠïŒãšVero现èïŒã¢ããªã«ãããªã¶ã«ã®èå
è
è现èðµïŒ2çš®ãçšããŠããŸããâ»å®éšã«ã¯ãŠã·èå
è¡æž
ðãçšããŸã
ãŠã€ã«ã¹ãå
¥ã£ãŠããïŒãšãããïŒæ£è
ã®æ€äœãå皮现èã«æ¥çš®ããïŒãããïŒå®éšã
ã€ã¡ãŒãžçã«ã¯ãããªæãããšæããŸãð
山圢çè¡çç ç©¶æãããåãããŸããã
ããã«ãVero现èããããŸãããïŒã¿ããªå€§å¥œãVero现èïŒ
CDCã®è«æã¯ããç¶ããŸãð
ãææåŸ24æéã§10ã®7ä¹ä»¥äžã«ïŒããŠã€ã«ã¹ããïŒå¢æ®ããVero现èãé€ãããããã®çŽ°èæ ªã«ãCPEïŒçްè倿§å¹æïŒã¯èªããããªãã£ãã
äžæ¹ãããèèãã现èïŒHUH 7.0ïŒãšããèå
è
现èïŒHEK-293TïŒã¯ããããªãŠã€ã«ã¹è€è£œãã瀺ãããããè
ºãã现èïŒA549ïŒã¯SARS CoV-2ã®ææã«å¯Ÿå¿ã§ããªãã£ããã
â»CPEïŒçްè倿§å¹æïŒãšã¯æ€äœãããããã现èãïŸïŸã¬ããšã§ãããŠã€ã«ã¹ã墿®ïŒå¹é€ïŒããã®ãçç±ãšããããããããŠã€ã«ã¹åé¢ã«æåããšåŒã³ãŸãããŠã€ã«ã¹ç ç©¶çã§ã®å€ãããã®ç¿æ £ã§ãããç§åŠçæ ¹æ ã¯ãããŸããã
å¹³ããèšãã°ããã®ãæ°åã³ãããŠã€ã«ã¹ãã¯äººéã«ã¯ææããªããšããããšãã圌ãã®èšèã§èšŒæãããšããããšã ããµã«ã®è è现èã«ããææããªãã
ã€ãŸããã®å®éšã§ãã³ããã墿®ããŠææã«ããïŸïŸãã ãã®ã¯Vero现èïŒã¢ããªã«ãããªã¶ã«ã®è è现èðµïŒã ãã ã£ããšããã®ã§ãã
â ãã ããVero现èã ããïŸïŸãã ãã®ã«ã¯çç±ããã£ãŠâŠ
ããããè
èã«æ¯æ§ãããããšãç¥ãããŠãã2çš®é¡ã®åŒ·åãªè¬å€ïŒã²ã³ã¿ãã€ã·ã³ãšã¢ã³ãã©ããªã·ã³ïŒãå ããŠåããŠãææãããã®ã§ããã
ãããŸã§äœåºŠãææããŠããããã«ãçµç¹ã飢ãããããæ¯æ®ºãããããªãéãããã®ãããªæ¥çš®ã§çµç¹ãæ»ã¬ïŒæº¶ããïŒããšã¯ç€ºãããŠããªãã
è èã«å¯Ÿããæ¯æ§ååŠç©è³ªïŒæçç©è³ªïŒãå ¥ããŠãã£ãããµã«ã ãããããªããè è现èã ããïŸïŸãã ã®ã§ãã
ãã®å³ã§ãäœåºŠã説æããŠããŸãã
â»ãå颿 ªããšèšã£ãŠãäœãåé¢ããŠããŸãã
â»æåã®ãµã³ãã«ã«ãæ°åã³ãããŠã€ã«ã¹ããå«ãŸããŠããã確ãããŠã¯ããŸãã
â»ååŠç©è³ªã䜿ããªããã°ãµã«è
è现èããïŸïŸãªãªããšããããšã«ãªããŸã
â»åãè
è现èã§ãããèå
è
现èïŒHEK-293TïŒã¯ãããããïŸïŸãã§ããŸãããã€ãŸãVero现èã¯éåžžã«ããªã±ãŒãã§ãããã奜ãã§å®éšã«äœ¿ãããçç±ã§ã¯ãªãããšæãããŸã
ã§ããããªã€ã«ãµããCDCã¯æ±ºããŠèªããªãã§ãããããããã®è«æã¯æžãããŠããéãã«åãåããšãããªããŸãð
åãããããäœåºŠãèªã¿è¿ããŠã»ããã
CDCã®ãŠã€ã«ã¹åŠè
ãã¡ã¯ã圌ãã®èŠè§£ã«åºã¥ããŠãSARS-CoV-2ãŠã€ã«ã¹ã人éã«ç¡å®³ã§ããããšã瀺ãæç¢ºãªèšŒæãè¡ã£ãããããå¯äžã®å¯èœãªçµè«ãªã®ã ããæ®å¿µãªããšã«ããã®çµæã¯åœŒãã®çµè«ã®äžã§èšåãããŠããããªãã
圌ãã¯åã«ããèšãã ãã§ãããæäŸã§ããå颿 ªã¯ãµã«ã®è
è现èã«ãã£ãŠã®ã¿å¹é€ããããã
ãããŸã§èªãã§ãããŠããããšãã
ã€ãŸããã®CDCè«æã¯ã³ããã¯ãµã«ðµããããããªãããšã蚌æããŠããã®ã§ãïŒïŒïŒ
ãªã®ã§ããè¡ã§ã³ããã«ããã£ããµã«ãšããéã£ãŠã倧äžå€«ã§ãã人ã«ã¯ãã€ããŸããã®ã§ðµ
â
ã¡ãªã¿ã«ãã®CDCè«æã§ããããã£ãäžäººã®æ€äœãã調ã¹ãŠããŸããã
MethodsïŒæ¹æ³ïŒ
Specimen CollectionïŒæ€äœæ¡åïŒ
ã®é
ã«ãã®ããã«ãããŸãð
ïŒClinical specimens from a case-patient who had acquired COVID-19 during travel to China and who was identified in Washington, USA, were collected as described (1).
ïŒäžåœãžã®æ
è¡äžã«COVID-19ãçºçãïŒç±³åœã¯ã·ã³ãã³å·ã§èº«å
ã確èªãããäžäººã®çäŸæ£è
ããïŒèšèŒãããŠããæ¹æ³ã§èšåºæ€äœãæ¡åãã(1)ïŒ
è±èªã¯ããããã®ãã¯ã£ããããããŸãããäœãšäžäººãã調ã¹ãŠããªãã®ã§ãã
ããããæå³ã§ãç§åŠã§ã¯ãããŸããã
ãããç±³CDCã®ãã³ããåé¢ã«æå=ååšèšŒæãè«æã®æŠèŠã§ãã
ã ããã¡ãããšããåé¢ïŒçŽç²åïŒèšé²ãæ±ãããããšåºããŸããð
äžçäžã®ç ç©¶æ©é¢ãåé¢ãšãããšåæ§ã®ããšããã£ãŠããŸãã
ãã®ãã³ããã¯ðµããããããªããä»¶ãå®ã¯æ¥æ¬ð¯ðµã§ã蚌æãããŠããŸãð
VeroE6/TMPRSS2现è = VeroE6ïŒãµã«è
è现èïŒã®ãæ¹è¯çãã
ããïŒã®ã¿ïŒã§ãã³ããå¹é€ïŒåé¢ïŒïŒãã§ããããšããçºè¡šã§ãã
ä»ãã¿ããªãã³ãããæããðµã®ã¯ã¯æðã«èªåã¯èãéããããšæã£ãŠã¿ãã®ã¯ã©ãã§ããããã
ãã®æðã§ã¯ä»ãã³ãããã§è
ããŠã¯ã¯ðã䜿ã£ãå€§èŠæš¡ãªðµæžãããè¡ãããŠãããããªãã¯åšãã®ðµãã¡ã«æžåœã«ç¶æ³ã説æããŸããã圌ãã¯çè§£ã§ããããŒããšãªãããã®é°è¬è«è
ãïŒããšå«ãã§éã«è¥²ãããã£ãŠããâŠ
ãããªç¶æ³ãªã®ã§ãã
â ãããâ ããããâ
2023/07/28远èš
æãã¬ãšããã§ãã®CDCè«æã®å
容ãåã£ãŠæšãŠãããŸããâ©ã8:30ïœ
ç¬åµçãªãããã³ã®ãŠã€ã«ã¹äºæ
ãJapanese Virus RiderãDr.ãµã ã»ãã€ãªãŒ
ATCCã¯ç ç©¶æ©é¢åãããŠã€ã«ã¹å颿 ªã販売ãµã€ãã§ãã
2022/04/06远èš
ã¢ã¡ãªã«ã®ãžã£ãŒããªã¹ãããžã§ã³ã»ã©ãããŒãæ°ã®èšäºããã玹ä»
å
容ã¯
2021幎7æ21æ¥ãCDCããããŸã§ã®PCRãããã2022幎以éã¯æ°ããããããPCRæ€æ»ã䜿ãããã«ãšãç¥ããããä»¶ã«ã€ããŠã§ãã
ã€ãŸãã³ãããå§ãŸã£ãŠä»¥æ¥äœ¿ãããŠããPCRãå®ã¯ç²ŸåºŠãäœãã£ããšCDCãèªããã®ã§ãããã®çç±ã¯CDCãæåã®SARS-CoV-2ã®PCRæ€æ»ãèæ¡ããæïŒ2020幎åé ïŒãŠã€ã«ã¹ã®æ€äœããªãã£ãããã
æ€äœïŒãŠã€ã«ã¹ã®å®ç©ãæšæ¬ïŒããªããŸãŸã«PCRãäœããã
ãšããããšã§ãããããã®ããŒãžã§èª¬æããCDC2020幎1æã®ðµè«æã§ã¯ãŠã€ã«ã¹ã¯åé¢ãããŠããªãã£ããšèªããããšã«ãªããŸãã
ããããç¥ããã«ãããšCDCãšFDAã¯ãã®åŸSARS-CoV-2ã®å®éã®ãŠã€ã«ã¹æšæ¬ãæ£è ããæ¡åããã®ã§ãåç ç©¶æ©é¢ã¯ããã䜿ã£ãæ°æ¹è¯PCRæ€æ»ã2022幎ãã䜿ãããã«ãšã®ããšã
ããã§èšäºèè
ã®ãžã§ã³ã»ã©ãããŒãããã倧å€ãç«è
¹ã
ãä»ãŸã§æ€æ»ããã¿ã©ã¡ãšããäºå®ãé ããŠäœ¿ã£ãŠãããçµç¹ãä»åŸã¯æ£ç¢ºãªæ€æ»ã䜿ããšèšã£ãŠããã®ã§ããä¿¡ããããŸããïŒã
ããŠæ¬åœã«CDCãšFDAã¯ãã®åŸSARS-CoV-2ã®å®éã®ãŠã€ã«ã¹æšæ¬ãæ£è ããæ¡åããã®ã§ããããïŒ
CDCã2021/10/26ð
ãïŒèŠæ±ãããæ¹æ³ã«ããåé¢ã¯ãããŸãããïŒCDCã§ã¯2020幎1æã«ãŠã€ã«ã¹ãåé¢ããŠããŸãããâ»culturing in cells=现èå¹é€
ãš2021幎10ææ«ã®åçã§çµå±ãŸã2020幎1æã®ðµåé¢è«æãåºããŠããŸãã
ã€ãŸããããããªãã®ã§ãã
FDAïŒç±³åœé£åå»è¬åå±ïŒ2022/01/03ð
FDAã«ããã®åŸã®åé¢èšé²ã¯ãªããã€ãŸãæšæ¬ã¯ãªããšããããšã§ãã
ã©ãããŒããã
ãã€ãŸãåœæã¯åãã€ããŠããããä»ã¯åãã€ããŠããªããåœæåœŒãã¯ãäŒãã§ãããã ä»ã§ã¯çå®ãèªã£ãŠãããšããããšãªã®ã§ããð
æåŸã¯ãã¡ããç®è
ãã¡ããCDCè«æãåè§£ãããã®ã§é¢çœãã§ãã
ã§ããã°èš³ãåŸæ¥èŒããããšæããŸãã
ãã¢ã³ããªã¥ãŒã»ã«ãŠããã³å士ãSARS-Cov-2ã®ãåé¢ãã«åè«ã











